Home Economics Doubts Mount About Valeant Pharmaceuticals’ Tax Structures

Doubts Mount About Valeant Pharmaceuticals’ Tax Structures

When you purchase through our sponsored links, we may earn a commission. By using this website you agree to our T&Cs.

MONTREAL – The disclosure by Valeant Pharmaceuticals International Inc. that it is under audit by the U.S. Internal Revenue Service is raising further doubts among tax specialists about the future of the Quebec-based drug company’s tax strategies. Valeant estimates it has achieved US$2.5-billion in tax and other “corporate structure” savings since merging with Ontario’s Biovail Corp.…

Valeant Pharmaceuticals under threat from tax audits, analysts say

Our Editorial Standards

At ValueWalk, we’re committed to providing accurate, research-backed information. Our editors go above and beyond to ensure our content is trustworthy and transparent.

Financial Post
Editor

Want Financial Guidance Sent Straight to You?

  • Pop your email in the box, and you'll receive bi-weekly emails from ValueWalk.
  • We never send spam — only the latest financial news and guides to help you take charge of your financial future.